In healthy immunocompetent women, how long does human papillomavirus type 18 or 45 remain detectable in the cervix?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of HPV 18/45 Cervical Infection

In healthy immunocompetent women, most HPV 18 and 45 infections become undetectable within 1-2 years, with approximately 90% clearing spontaneously without intervention. 1

Natural Clearance Timeline

The evidence consistently demonstrates that HPV infections, including high-risk types 18 and 45, follow a predictable clearance pattern:

  • Most infections (approximately 90%) become undetectable within 1-2 years of initial detection through immune-mediated clearance 1
  • The immune system clears HPV infection most of the time in healthy individuals, though in some persons HPV infection does not resolve 1
  • Clearance rates are highest in younger women, with women under 30 years showing approximately 60% regression rates even for established CIN2 lesions 1

Age-Related Differences in Persistence

The duration HPV remains detectable varies significantly by age:

  • Women under 30 years: HPV infection rates can be as high as 43%, but the overwhelming majority of these infections resolve spontaneously, including those due to high-risk genotypes like HPV 18 and 45 1
  • Women over 30 years: Persistent infections are more common, and women with HPV positivity in this age group have higher risk of persistent disease 2
  • Following rapid accumulation of incident infections after onset of sexual activity (women <20 years), there is a transition favoring virus clearance soon after age 25 3

What "Persistence" Actually Means

Persistent infection is typically defined as the same HPV type remaining detectable for more than 12-24 months 1:

  • One-year and two-year HPV persistence, especially by HPV 16 (though similar principles apply to HPV 18 and 45), strongly predict progression to high-grade lesions 1
  • Women whose infections persist beyond 1-2 years are at significant risk of developing precancerous lesions 1
  • The longer an HPV infection persists, the less likely a patient is to clear the infection 1

Clinical Implications for HPV 18 and 45 Specifically

While HPV 16 is most studied, HPV 18 and 45 have distinct characteristics:

  • HPV 18 accounts for 10-15% of cervical cancers and causes a greater proportion of glandular cancers (adenocarcinoma) compared to squamous cell carcinoma (approximately 32% vs. 8%) 1
  • HPV types 16,18, and 45 together account for 85.7% of CIN 2-3 lesions that progress, with 88.2% of CIN 3 lesions being positive for one or more of these types 4
  • Detection of high-risk HPV infection does not indicate when the infection was acquired, and HPV infection can be present for many years before it is detected 1

Important Caveats

The stepwise development from HPV acquisition to invasive cancer takes an average of 20 years, with the longest interval being from high-grade lesions to invasive cancer 1:

  • This prolonged timeline reflects the time needed for random genetic events and viral integration 1
  • However, some cases can develop more rapidly than the average 1
  • Re-appearance of the same HPV type after documented clearance is rare (only 3.7% showed definite clearance and re-appearance), and progression to CIN2+ after re-appearance is extremely uncommon 5

Postmenopausal Considerations

A notable exception to typical clearance patterns occurs at postmenopause:

  • Failure to eradicate the virus at postmenopause is not uncommon, explaining a second peak in HPV prevalence in many populations 3
  • The mechanisms making some women over 55 years unable to clear infections that younger women typically clear remain incompletely understood 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cervical Cancer Screening Guidelines for Women Over 30

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2009

Related Questions

What are the treatment options for a patient with a Pap (Papanicolaou) smear positive for Human Papillomavirus (HPV) but negative for high-risk types 16, 18, and 45?
What are the next steps for a 41-year-old female with normal Pap (Papanicolaou) cytology but positive Human Papillomavirus (HPV) test for high-risk strains 18/45?
Can Human Papillomavirus (HPV) recur after it has been cleared?
What is the recommended management for a 34-year-old female with a first Pap (Papanicolau) smear showing Human Papillomavirus (HPV) 16 positive result?
How should a 37‑year‑old woman with normal cervical cytology and a positive high‑risk HPV test (non‑16/18) be managed?
In a 35‑week pregnant woman with maternal hypertension and fetal intra‑uterine growth restriction who now has an elevated umbilical‑artery Doppler (high resistance), what is the appropriate management?
Why switch from enoxaparin to edoxaban for long‑term anticoagulation after the acute phase of venous thromboembolism or atrial fibrillation?
What treatments can restore rectal sensation in men with an overstretched (lax) puborectalis muscle?
What medication is recommended for a 30-year-old female with bipolar II disorder presenting with a depressive episode and suicidal ideation who is allergic to lamotrigine?
What are the recommended treatments for acute bacterial prostatitis, chronic bacterial prostatitis, and chronic prostatitis/chronic pelvic pain syndrome?
What is the recommended isoprenaline (isoproterenol) infusion dose and titration for an adult with symptomatic bradycardia when atropine is ineffective or contraindicated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.